- PII
- S19982860S0132342325050174-1
- DOI
- 10.7868/S1998286025050174
- Publication type
- Article
- Status
- Published
- Authors
- Volume/ Edition
- Volume 51 / Issue number 5
- Pages
- 920-930
- Abstract
- The PRAME antigen (Preferentially Expressed Antigen in Melanoma), which belongs to the group of cancer-testis antigens and is expressed in various tumor types, represents an attractive target for targeted cancer therapy. In this study, a humanized antibody (6H8Hu) was developed based on the monoclonal antibody 6H8 specific to the PRAME protein. The antibody was produced in CHO cells. It was shown that the humanized antibody retains the high affinity of the parental mAb to the antigen (1.2 nM), binds to both recombinant and native PRAME protein, inhibits the proliferation of PRAME-positive human melanoma cell line Mel Ibr, and suppresses tumor nodule growth in vivo to a degree comparable to that of the murine antibody 6H8 and the cytostatic agent melphalan.
- Keywords
- PRAME гуманизированные антитела иммунотерапия опухолей
- Date of publication
- 01.05.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 7
References
- 1. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G. // Immunity. 1997. V. 6. P. 199–208. https://doi.org/10.1016/s1074-7613 (00)80426-4
- 2. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., Verdijk P., van Veelen P.A., Kloosterman-Joosten A.M., Vissers D.C., ten Bosch G.J., Kester M.G., Sijts A., Wouter Drijfhout J., Ossendorp F., Offringa R., Melief C.J. // J. Exp Med. 2001. V. 193. P. 73–88. https://doi.org/10.1084/jem.193.1.73
- 3. Greiner J., Schmitt M., Li L., Giannopoulos K., Bosch K., Schmitt A., Dohner K., Schlenk R.F., Pollack J.R., Dohner H., Bullinger L. // Blood. 2006. V. 108. P. 4109–4117. https://doi.org/10.1182/blood-2006-01-023127
- 4. Weber G., Caruana I., Rouce R.H., Barrett A.J., Gerdemann U., Leen A.M., Rabin K.R., Bollard C.M. // Clin. Cancer Res. 2013. V. 19. P. 5079–5091. https://doi.org/10.1158/1078-0432.ccr-13-0955
- 5. Schneider V., Zhang L., Rojewski M., Fekete N., Schrezenmeier H., Erle A., Bullinger L., Hofmann S., Gotz M., Dohner K., Ihme S., Dohner H., Buske C., Feuring-Buske M., Greiner J. // Int. J. Cancer. 2015. V. 137. P. 2083–2092. https://doi.org/10.1002/ijc.29583
- 6. Babiak A., Steinhauser M., Gotz M., Herbst C., Dohner H., Greiner J. // Oncol. Rep. 2014. V. 31. P. 384– 390. https://doi.org/10.3892/or.2013.2804
- 7. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., Bergmann L., Schmitt M. // Exp. Hematol. 2000. V. 28. P. 1413–1422. https://doi.org/10.1016/s0301-472x (00)00550-6
- 8. Hermes N., Kewitz S., Staege M.S. // Curr. Cancer Drug Target. 2016. V. 16. P. 400–414. https://doi.org/10.2174/1568009616666151222151818
- 9. Larina M.V., Finashutina Y.P., Lyzhko N.A., Misyurin V.A., Novoseletsky V.N., Dolgikh D.A., Solopova O.N., Moysenovich A.M., Balabashin D.S., Aliev T.K., Misyurin A.V., Kirpichnikov M.P. // Russ. J. Bioorg. Chem. 2022. V. 48. P. 360–371. https://doi.org/10.1134/S1068162022020133
